The randomized, double-blind study evaluates the efficacy and safety of the drug, with a primary endpoint focused on patients achieving an ASAS40 response by the 16th week. Zemprocitinib, a second-generation selective JAK1 inhibitor, is designed to minimize the off-target effects often seen in earlier iterations of the class. Previous data from rheumatoid arthritis and atopic dermatitis trials suggest the medication offers both rapid efficacy and a favorable safety profile compared to placebos.
Lynk Pharmaceuticals Completes Enrollment for Ankylosing Spondylitis Trial
Lynk Pharmaceuticals has finalized enrollment for its Phase III clinical trial of zemprocitinib, an oral treatment targeting active ankylosing spondylitis. By securing 352 participants, the company moves closer to offering a potential alternative for patients who struggle with current inflammatory disease therapies and their associated long-term safety concerns.
Dr. Zhao-Kui Wan, founder and CEO of Lynk Pharmaceuticals, noted that this milestone serves to validate the clinical value of the therapy for a condition that frequently leads to severe spinal stiffness and impaired physical function. The company, which maintains a research focus on the JAK-STAT signaling pathway, plans to use the data gathered from these 352 patients to support forthcoming regulatory filings. As the study progresses through treatment and follow-up phases, the firm remains committed to expanding its pipeline of small-molecule therapies intended to replace more invasive biologic treatments.
Comments (0)
No comments yet. Be the first!